Don’t follow the herd into the market abyss

In this AFR article, previous Conference Fund Manager, Jun Bei Liu discusses the sharemarket and finding incredible investment opportunities in contrarian ideas.

Jun Bei Liu

Don’t follow the herd into the market abyss

October 17, 2021
In this AFR article, previous Conference Fund Manager, Jun Bei Liu discusses the sharemarket and finding incredible investment opportunities in contrarian ideas.
Read Transcript

The sharemarket has been on a wild ride for the past 19 months, from highs to lows and back again on the back of a medley of concerns from bulls and bears.

These day-to-day fears take in the possibility of uncontrollable inflation, imminent recession, breakdown of global trade, and of course,
let’s not forget the ongoing effects of the pandemic and the ever-present possibility of wars.

As an equity investor, the sharemarket can feel like a rollercoaster when every one of those fears is magnified through share prices. Despite being an investor for close to two decades, I still find myself wondering – has it always been like this?

The answer is yes. The sharemarket largely reflects company earnings and investor mood. Rationally, company earnings should determine the share price but sometimes investor mood can collectively overshadow any company’s performance. This leads to opportunities for astute investors who focus on the companies rather than their behavioural biases.

Take BHP as an example. Its share price has come off close to 40 per cent from the fear of the contagion effect of Evergrande on China’s economy, along with weak iron ore prices. On the surface, however, taking a look at BHP’s earnings split, iron ore contributes less than 40 per cent of BHP’s revenue in FY22. This tells you that iron ore prices will have some impact on earnings, but not as much as 40 per cent.

What is not talked about is that close to 10 per cent of BHP’s revenue is from its energy asset, which is due to be folded into the new Woodside. The global shortages of energy have sent energy prices skyrocketing and energy majors, such as Woodside, have outperformed substantially, by a margin of more than 50 per cent during the same period.

As a rational investor, we don’t believe such price discrepancy is likely to be sustained.

Star Entertainment is another company that has seen extreme share price movement recently, down close to 30 per cent at one point. Before the company even had a chance to respond to the media reports, a clear “shoot first and ask questions later” mentality took hold with investors.

Clearly, these are serious allegations, but a fall of 30 per cent would send the share price lower than its book value of over $3.80, which in our opinion was too much. Particularly at a time when its earnings are on the cusp of recovering sharply and its other reopening peers are all trading at pre-COVID-19 highs.

Another name we like to bring up here is one of our all-time favourites, a2 Milk. Its share price has been under significant pressure over the past 12 months, as border closures presented significant challenges for big parts of a2’s product distribution channel, the daigou.

At the same time, early pandemic panic pantry-stocking by Chinese mothers led to too much inventory sitting in people’s houses that needed to be cleared – a curse for a premium consumer goods company. A2 Milk’s share price fell more than 60 per cent since its full-year result in August 2020. For most investors, it was too hard to see past the current year’s earnings.

This is despite many of these disruptions being temporary and incrementally positive news on improving conditions over the past four months. As a premium branded business, over the past decade, a2 has captured the hearts and minds of Asian consumers. Its English-label and Chinese-label products are highly sought after hence why, when the pandemic first hit, Chinese mothers stocked up as much infant formula as they could find on the shelves.

A2 also has a very strong balance sheet, with a net cash position of $720 million.

These are just some examples of companies that have been mispriced when investors succumb to their behavioural biases. Be contrarian and don’t let another salesperson tell you that buying Wesfarmers is a reopening trade.

There are plenty of investment opportunities, investors just need to be discerning.

 

The article was originally published by The AFR.

Licensed by Copyright Agency. You must not copy this work without permission.

 

 

The sharemarket has been on a wild ride for the past 19 months, from highs to lows and back again on the back of a medley of concerns from bulls and bears.

These day-to-day fears take in the possibility of uncontrollable inflation, imminent recession, breakdown of global trade, and of course,
let’s not forget the ongoing effects of the pandemic and the ever-present possibility of wars.

As an equity investor, the sharemarket can feel like a rollercoaster when every one of those fears is magnified through share prices. Despite being an investor for close to two decades, I still find myself wondering – has it always been like this?

The answer is yes. The sharemarket largely reflects company earnings and investor mood. Rationally, company earnings should determine the share price but sometimes investor mood can collectively overshadow any company’s performance. This leads to opportunities for astute investors who focus on the companies rather than their behavioural biases.

Take BHP as an example. Its share price has come off close to 40 per cent from the fear of the contagion effect of Evergrande on China’s economy, along with weak iron ore prices. On the surface, however, taking a look at BHP’s earnings split, iron ore contributes less than 40 per cent of BHP’s revenue in FY22. This tells you that iron ore prices will have some impact on earnings, but not as much as 40 per cent.

What is not talked about is that close to 10 per cent of BHP’s revenue is from its energy asset, which is due to be folded into the new Woodside. The global shortages of energy have sent energy prices skyrocketing and energy majors, such as Woodside, have outperformed substantially, by a margin of more than 50 per cent during the same period.

As a rational investor, we don’t believe such price discrepancy is likely to be sustained.

Star Entertainment is another company that has seen extreme share price movement recently, down close to 30 per cent at one point. Before the company even had a chance to respond to the media reports, a clear “shoot first and ask questions later” mentality took hold with investors.

Clearly, these are serious allegations, but a fall of 30 per cent would send the share price lower than its book value of over $3.80, which in our opinion was too much. Particularly at a time when its earnings are on the cusp of recovering sharply and its other reopening peers are all trading at pre-COVID-19 highs.

Another name we like to bring up here is one of our all-time favourites, a2 Milk. Its share price has been under significant pressure over the past 12 months, as border closures presented significant challenges for big parts of a2’s product distribution channel, the daigou.

At the same time, early pandemic panic pantry-stocking by Chinese mothers led to too much inventory sitting in people’s houses that needed to be cleared – a curse for a premium consumer goods company. A2 Milk’s share price fell more than 60 per cent since its full-year result in August 2020. For most investors, it was too hard to see past the current year’s earnings.

This is despite many of these disruptions being temporary and incrementally positive news on improving conditions over the past four months. As a premium branded business, over the past decade, a2 has captured the hearts and minds of Asian consumers. Its English-label and Chinese-label products are highly sought after hence why, when the pandemic first hit, Chinese mothers stocked up as much infant formula as they could find on the shelves.

A2 also has a very strong balance sheet, with a net cash position of $720 million.

These are just some examples of companies that have been mispriced when investors succumb to their behavioural biases. Be contrarian and don’t let another salesperson tell you that buying Wesfarmers is a reopening trade.

There are plenty of investment opportunities, investors just need to be discerning.

 

The article was originally published by The AFR.

Licensed by Copyright Agency. You must not copy this work without permission.

 

 

Disclaimer: This material has been prepared by Australian Financial Review, published on Oct 17, 2021. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.